Clinical Social Workers in Haleiwa, HI Accepting Medicare

5 Clinical Social Workers found. Showing 1 - 5

Ms. Heather N Jablonski, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 66-250 Kamehameha Hwy Ste D204, Haleiwa, HI 96712 Phone: 808-391-5617

Ms. Olivia Harkins-pignolet, LCSW, CSAC Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 66-250 Kamehameha Hwy # 204, Haleiwa, HI 96712 Phone: 808-277-8848

Sonja Christine Bigalke-bannan, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 59-777 Pupukea Rd, Haleiwa, HI 96712 Phone: 808-388-4974

Andi Ley, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 58-130 Kamehameha Hwy, Haleiwa, HI 96712 Phone: 480-987-2053

Megan Louise Salgado, LCSW, CSAC Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 59-791 Kanalani Pl, Haleiwa, HI 96712 Phone: 808-256-7675

News Archive

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

Researchers adopt new approach to treating advanced prostate cancer

Scientists have proposed a new approach to preventing the proliferation of prostate tumor cells that are no longer responding to treatment. Prostate cancer can usually be cured via surgical removal of the tumor and/or the use of radiotherapy, but in one-fifth of cases, patients also require treatment with drugs to continue removing tumor cells. However, these drugs are only effective for up to three years, after which the cancer continues to develop.

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).

Sirona fourth quarter revenue increases 19.6% to $218.8 million

Sirona, the dental technology leader, today announced its financial results for the quarter and fiscal year ended September 30, 2011.

Positive results from POZEN's PA8140-102 Phase 1 bioavailability study

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that the results from a Phase 1 study, PA8140-102, demonstrated that PA8140, POZEN's proprietary combination of aspirin (81 mg) and omeprazole (40 mg), had comparable bioavailability relative to the reference listed product, enteric-coated (EC) aspirin (81 mg).

Read more Medical News

› Verified 1 days ago